All In Biotech

Drug Trial Radar · NCT07946107

BHB-1893 vs. Placebo for Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

A Phase 3, Multi-region, Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of BHB-1893 in Adults With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Dec 2029

Study completion Jan 2030

Sponsor

Lead sponsor
Braveheart Bio, Inc.Industry
Sponsor type
Industry
First posted
Nov 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this trial is to find out whether BHB-1893 works better than placebo in adults with non-obstructive hypertrophic cardiomyopathy (nHCM).

Conditions

  • Cardiomyopathy, Hypertrophic Non-Obstructive

Interventions

  • BHB-1893Drug

    Tablets for oral use

  • PlaceboOther

    Tablets for oral use

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score (KCCQ-CSS)Time frame: Baseline, Week 36
  2. Change from Baseline in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise (CPET)Time frame: Baseline, Week 36

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.